69232-47-9

Basic information

• Product Name: ACETIC ACID ACETOXY-(4-CHLOROSULFONYLPHENYL)METHYL ESTER
• Synonyms: ACETIC ACID ACETOXY-(4-CHLOROSULFONYLPHENYL)METHYL ESTER;(4-(chlorosulfonyl)phenyl)methylene diacetate
• CAS NO: 69232-47-9
• Molecular Formula: C₁₁H₁₁ClO₆S
• Molecular Weight: 306.72
• Mol File: 69232-47-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: 111-113 °C(Solv: acetone (67-64-1); ligroine (8032-32-4))
• Boiling Point: 406.457 °C at 760 mmHg
• Flash Point: 199.618 °C
• Appearance: /
• Density: 1.419 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.535
• Storage Temp.: 2-8°C
• CAS DataBase Reference: ACETIC ACID ACETOXY-(4-CHLOROSULFONYLPHENYL)METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: ACETIC ACID ACETOXY-(4-CHLOROSULFONYLPHENYL)METHYL ESTER(69232-47-9)
• EPA Substance Registry System: ACETIC ACID ACETOXY-(4-CHLOROSULFONYLPHENYL)METHYL ESTER(69232-47-9)

Safety Data

• Hazardous Substances Data: 69232-47-9(Hazardous Substances Data)

Usage

General Description

Acetic acid acetoxy-(4-chlorosulfonylphenyl)methyl ester is a chemical compound used in the production of pesticides and herbicides. It belongs to the family of acetic acid esters, which are commonly used as solvents and intermediate chemicals in various industrial processes. Acetic acid acetoxy-(4-chlorosulfonylphenyl)methyl ester is known for its strong herbicidal and pesticidal properties, making it a key ingredient in the development of agricultural products. Additionally, it is also used in the chemical industry as a reagent in organic synthesis and as a precursor in the production of pharmaceuticals and other organic compounds. However, it is important to handle this chemical with care, as it can be toxic and is a potential irritant to the skin and eyes.

InChI:InChI=1/C11H11ClO6S/c1-7(13)17-11(18-8(2)14)9-3-5-10(6-4-9)19(12,15)16/h3-6,11H,1-2H3

Upstream product

• 108-24-7 acetic anhydride 
• 64-19-7 acetic acid 
• 98-59-9 p-toluenesulfonyl chloride 
• 4525-33-1 dimethyl dicarbonate 

Downstream Products

• 857005-28-8 4-diacetoxymethyl-benzenesulfonic acid anilide 
• 874514-41-7 4-diacetoxymethyl-benzenesulfonic acid p-phenetidide 
• 1219449-55-4 (4-(pyrrolidin-1-ylsulfonyl)phenyl)methylene diacetate 
• 854746-07-9 (acetyloxy)-{4-[({(1S,2R)-1-benzyl-2-hydroxy-3-[({4-[(E)-(hydroxyimino)methyl]phenyl}sulfonyl)(isobutyl)amino]propyl}amino)sulfonyl]phenyl}methyl Acetate 
• 741704-99-4 C₁₆H₂₁NO₆S 
• 77547-12-7 p-(N,N-diethylsulfonamido)benzaldehyde 
• 77547-10-5 4-(morpholin-4-ylsulfonyl)benzaldehyde 
• 149556-85-4 4-formyl-N-(pyridin-2-yl)benzenesulfonamide 
• 100885-75-4 N-isonicotinoyl-N'-(4-thiosemicarbazonomethyl-benzenesulfonyl)-hydrazine 
• 100728-54-9 N-(4-formyl-benzenesulfonyl)-N'-isonicotinoyl-hydrazine 
• 179057-22-8 4-formyl-N-phenylbenzenesulfonamide 
• 3240-35-5 4-formyl-benzenesulfonamide 

Relevant articles and documents

SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS

The present invention belongs to the field of EPl receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EPl receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EPl receptor as well as to pharmaceutical compositions comprising them.

METHOD AND COMPOSITIONS FOR TREATING HIV INFECTIONS

Described herein are compounds and compositions that are useful in the treatment of HIV, AIDS, and AIDS-related diseases. In addition, compounds are described herein that are capable of inhibiting the dimerization of HIV proteases.

Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors

As a continuation of the recently communicated discovery of oximinoarylsulfonamides as potent inhibitors of HIV-1 aspartyl protease, compounds bearing pyridylmethyl substituents at P3 were designed and synthesized. Potent analogs in this series provided low single-digit nanomolar EC50 values against both wild-type HIV and resistant mutant virus (A17), attenuated some 3- to 12-fold in the presence of 50% human serum. Pharmacokinetic results for compounds in this series showed good to excellent exposure when co-administered orally with an equal amount of ritonavir (5 mg/kg each) in the rat, with average AUC >8 μg h/mL. Similar dosing in dog resulted in significantly lower plasma levels (average AUC i = 2.4 nM).